South African Geranium Root Extract
Also known as: South African geranium, EPs 7630, Umckaloabo, Pelargonium extract, Pelargonium sidoides
Overview
Pelargonium sidoides is a flowering plant endemic to South Africa, traditionally used in indigenous medicine. The root extract, known as EPs 7630, is made through a hydroethanolic extraction process and is primarily utilized in treating acute viral respiratory tract infections, including bronchitis and the common cold. Rich in oligomeric prodelphinidins, minerals, peptides, and benzopyranones, it stands out for its complex composition and medicinal properties. This extract is classified as an 'other extract' by the European Pharmacopoeia, which means it does not have specified content thresholds. Numerous studies, including clinical trials and systematic reviews, underscore its efficacy in relieving respiratory symptoms, demonstrating its vital role in respiratory health management.
Benefits
EPs 7630 has several research-backed benefits. A notable randomized controlled trial involving 220 children indicated a significant reduction in bronchitis severity scores (4.4 points for EPs 7630 versus 2.9 points for placebo; P < 0.0001). Systematic reviews support its effectiveness in alleviating cold symptoms and accelerating recovery. Additional research suggests it might reduce the frequency of COPD exacerbations. It also exhibits immunomodulatory and antiviral properties, making it particularly beneficial for both children and adults with respiratory conditions, with symptom improvements typically observable within 7-10 days of beginning treatment.
How it works
EPs 7630 exerts its effects through multiple biological pathways, showcasing antibacterial and antiviral activities that inhibit pathogen growth. It modulates immune responses, enhancing the body's capacity to combat viral infections, and may also support the integrity of the epithelial barrier crucial for respiratory health. While specific molecular targets are still being identified, the active compounds, especially oligomeric prodelphinidins, play a key role in mediating these effects.
Side effects
EPs 7630 is generally well-tolerated, having been assessed in clinical trials with over 10,000 participants showing a favorable safety profile where no common side effects exceeded 5%. Rare adverse effects have not been significantly reported. However, potential drug interactions may occur with immunosuppressants and anticoagulants, as EPs 7630 could potentially weaken immunosuppressive effects or increase bleeding risks. While no specific contraindications have been identified, caution is warranted when combined with these medications. The extract is considered safe for children and adolescents based on the available evidence.
Dosage
The recommended dosage of EPs 7630 varies by age. For children aged 1-6, the recommended dose is 10 drops; for those aged 7-12, 20 drops; and for teens aged 13-18, 30 drops, each taken three times daily. Adults should take between 30-60 drops (1.5-3 mL) three times daily. It is crucial to commence treatment within 48 hours of the onset of symptoms for optimal effectiveness. The extract is available in both solution and tablet forms, with the solution being the most widely used. Although a maximum safe dose has not been firmly established, following the suggested dosages is effective and considered safe.
FAQs
Is EPs 7630 safe?
Yes, EPs 7630 is generally considered safe, but potential interactions with certain medications like anticoagulants should be monitored.
When should I start taking EPs 7630?
It is recommended to begin treatment as soon as symptoms appear, ideally within 48 hours for best efficacy.
What results can I expect?
Patients usually see a reduction in respiratory symptoms, such as those from acute bronchitis, within 7-10 days of starting treatment.
Can I confuse EPs 7630 with other geranium products?
Be cautious; EPs 7630 is different from rose geranium oil or spotted geranium, and they are not interchangeable.
Research Sources
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779306/ – This clinical study assessed the effects of EPs 7630 on acute bronchitis in children and found a significant improvement in bronchitis severity, underscoring the extract's efficacy.
- https://pubmed.ncbi.nlm.nih.gov/20524722/ – A systematic review of the clinical efficacy of EPs 7630 demonstrates its significant role in reducing symptoms and accelerating recovery from respiratory infections.